Targeted Immunotherapy for Pre-Invasive High Risk Human Papillomavirus Disease
Please arrive 5 minutes before the Seminar begins to gain building access
High risk human papillomaviruses (hrHPV) are responsible for over 0.5 million cases of cervical cancer and 70,000 anogenital and oropharyngeal cancers annually. Invasive lesions represent the end stage of a minority of persistent infections that cause progressive dysplasia over many years. Licensed preventive vaccines do not prevent disease in women with pre-existing hrHPV infection. I will discuss progress towards development of therapeutic vaccines that harness cell-mediated immune responses to eliminate pre-invasive lesions and persistent infections.
Date: 28 February 2018, 12:00 (Wednesday, 7th week, Hilary 2018)
Venue: Medawar Building, off South Parks Road OX1 3SY
Venue Details: Level 30 Seminar Room
Speaker: Lucy Dorrell (University of Oxford)
Organising department: Department of Zoology
Organiser: Ramona Kantschuster (Dept of Zoology)
Organiser contact email address:
Host: Professor Sunetra Gupta (University of Oxford)
Part of: Peter Medawar Building Seminars
Topics: Dysplasia, Papillomaviruses, Vaccines
Booking required?: Not required
Cost: FREE
Audience: UK Science Community
Editor: Ramona Kantschuster